Award criteria include visionary innovation, performance, and customer impact

TELFORD, Pa., Feb. 29, 2024 /PRNewswire/ -- Dr?ger, an international leader in medical and safety technologies, today announced that Frost & Sullivan has selected the company for its 2024 Best Practices Company of the Year Award in the global respiratory care devices industry. Frost & Sullivan's selection process involves identifying companies that consistently develop growth strategies based on a visionary understanding of the future and effectively address new challenges and opportunities employing best practices and strategic analytics across a value chain.

"Today's healthcare decision makers are looking beyond devices to determine the value a product brings to their critical care environments," said President and CEO for Draeger, Inc., Lothar Thielen. "This award validates Dr?ger's approach of combining best-in-class products, cost-effective accessories, and service solutions – which together deliver unmatched value to the hospitals we support."

Addressing hospital needs by offering easy-to-use and cost-conscious solutions
According to Utkarsha Soundankar, senior research analyst at Frost & Sullivan, "Dr?ger has become one of the leading respiratory device vendors for its enhanced clinical outcomes, product quality, long-term customer support, and ongoing education tools, all of which assist in offering patient safety and enhanced care."

Dr?ger developed its new Evita V600, V800 and Babylog VN800 ventilators based on customer requirements for improving patient safety, patient outcomes, and hospital workflow. These devices can provide various modes of ventilation – such as high-flow O₂ therapy, non-invasive ventilation, and invasive ventilation modes – using the same accessories. This eliminates the need to use multiple devices for critically ill patients who require different types of respiratory support, thereby streamlining workflow and reducing equipment costs.

Providing visionary scenarios through mega trends
Frost & Sullivan salutes Dr?ger for introducing first-to-market solutions and continually investing in the development of new technologies. One such example is Dr?ger's research collaboration with STIMIT for the investigation of ventilator-induced diaphragmatic dystrophy (VIDD). STIMIT is developing non-invasive diaphragm stimulation for preserving diaphragm thickness. An FDA-approved clinical trial for this emerging technology began in January 2024.

Fostering excellent customer ownership and service experiences
Used by leading hospitals worldwide, Dr?ger's respiratory devices are clinically validated, with detailed consideration for the hospital's specific application. To support hospital infection control protocols, Dr?ger designs its devices with smooth services and minimal nooks that can harbor infectious agents. The company has also developed an extensive line of single-patient use and reusable valves.